Trimethoprim (2,4,diamino-5-(3',4',5'-trimethoxybenzyl) pyrimidine) is an antifolic acid agent developed by workers at the Wellcome Research Laboratories (Hitchings, Elion, Falco, Russell, Sherwood, and Vanderwerff, 1950a, b) . It was found to inhibit the enzyme dihydrofolic acid reductase in bacteria with little or none of this activity against the corresponding enzymes of mammalian species (Hitchings and Bushby, 1961; Hitchings and Burchall, 1965) . Of special interest was the observation in vitro and in vivo that the compound markedly potentiates the antibacterial activity of sulphonamides; this effect reduces the concentration of each drug required for the systemic treatment of bacterial infections and has made it possible to treat successfully infections due to sulphonamide-resistant organisms (Elion, Singer, and Hitchings, 1954 and Hitchings, , 1960 .
Trimethoprim has been tried as the sole chemotherapeutic agent in a small number of patients with Proteus infections with encouraging results (Schneider, Schwarzenberg, Cattan, Schlumberger, Amiel, and Mathe, 1965) . The combination of Trimethoprim and sulphonamide was first tested in man in a patient with Proteus septicaemia by Noall, Sewards, and Waterworth (1962) and in a similar case by Cooper and Wald (1964) ; both patients made a full recovery.
Present Investigation Gonorrhoea in men was chosen for this trial for two reasons:
(1)
The effect of antibiotic treatment can usually be simply and rapidly determined in these patients.
(2) The treatment of gonorrhoea has become less satisfactory in recent years owing to the increasing proportion of cases resistant to penicillin and other antibiotics (Brown, 1961; Storck, Muller, and Rinderknecht, 1966 Tables I  and II. (1) Trimethoprim Alone (100 mg. four times daily for 4 days).
The number of patients in this group had to be curtailed when it became obvious that the compound had no appreciable effect on the clinical course of the infection. No adverse side-effects to this treatment were noted and subsequent response to penicillin or tetracycline was satisfactory.
(2) Sulphatriad Alone (1 g. four times daily for 4 days).
The results were highly unsatisfactory and the number of patients so treated was restricted. There were no side-effects and re-treatment of failures with penicillin was successful.
(3) Trimethoprim and Sulphatriad. (4) Gantanol Alone (1 g. twice daily for 4 days).
This sulphonamide is rapidly absorbed and slowly excreted and maintains effective serum levels after twice daily administration (Kiser, Bormel, Young, and Silverstein, 1961) . The results were no better than with sulphatriad. There were no side-effects. (Table III) .
There is no significant difference in the cure-rate with these different treatments (P > 0 -05). The incidence of non-gonococcal urethritis after successful elimination of gonorrhoea was significantly higher in those receiving penicillin than in those receiving the other drugs (0-05 >P >0-02).
Penicillin Failures treated with Trimethoprim/Sulphatriad Combination Fifteen patients were initially treated with 1 -2-2-4 mega units procaine penicillin but failed to respond, and fourteen of these were cured with the full dose of Trimethoprim/sulphatriad.
Of another five cases of penicillin failure treated with reduced doses of Trimethoprim/sulphatriad, three were cured and two failed; one of the failures was subsequently cured with the full dose of the combined drugs, and the other with Trimethoprim/Gantanol.
Of a further nine cases of penicillin failure which also failed to respond to one or more other antibiotics, seven were cured with the full dose of Trimethoprim/sulphatriad and one defaulted.
Thus the overall results show that penicillin and other antibiotic failures respond to the Trimethoprim/sulphonamide combination as well as untreated cases.
Allergy to Penicillin Only three patients gave a clear history of allergic reactions to penicillin and they responded to Trimethoprim/sulphatriad without ill-effects.
Discussion
When assessing any treatment for gonorrhoea, the principal difficulty is to distinguish relapse from re-infection. Willcox (1964) argued in favour of evaluating therapeutic results within 1 or 2 weeks of treatment when there is less likelihood of re-infection causing confusion. It is general experience that about half of the patients who do not respond to treatment show little or no improvement from the outset and that the other half relapse after a few days, at a time when the number of re-infections is probably negligible (Dunlop, 1949; Willcox, 1964) . With these considerations in mind we classed all recurrences in the first 2 weeks after treatment as failures, and the few which appeared after this period as fresh infections, provided further sexual exposure was admitted. Another source of difficulty in evaluating treatment is a high default rate. In this series a special effort was made to observe the patients for a reasonable period after treatment, and the default rate of 15 per cent. of the total of 425 patients is considered as fairly satisfactory.
Sulphonamides were successful in 80 to 90 per cent. of cases of gonorrhoea during their most effective but alas short-lived period before 1942 (Lloyd, Erskine, and Johnson, 1940; Laird, 1942) . (Kiser and others, 1961) ; as the absorption and excretion rate of Trimethoprim is similar to that of Gantanol these two drugs are better matched to act together. Our experience with varying the proportion of Trimethoprim to sulphatriad showed that a comparatively small dose of Trimethoprim is effective in potentiating a much larger amount of sulphonamide and this is in line with the results of in vitro experiments using the gonococcus Waterworth, 1966) . In this respect the gonococcus appears to behave differently from other organisms tested (Hitchings, 1966 
